Selection of non-small cell lung cancer patients for intercalated chemotherapy and tyrosine kinase inhibitors

Matjaz Zwitter1,2, Antonio Rossi3, Massimo Di Maio4, Maja Pohar Perme5, Gilberto Lopes6

1 Institute of Oncology Ljubljana, Ljubljana, Slovenia
2 Faculty of Medicine, University of Maribor, Maribor, Slovenia
3 Division of Medical Oncology, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo (FG), Italy
4 Division of Medical Oncology, Mauriziano Hospital, Oncology Department, University of Turin, Torino, Italy
5 Institute for Biostatistics and Medical Informatics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
6 Centro Paulista de Oncologia e HCor Onco, members of the Oncoclínicas do Brasil Group, Sao Paulo, Brazil and Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA

Background. When treating patients with advanced non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors and chemotherapy, intercalated schedule with time separation between the two classes of drugs should avoid their mutual antagonism. In a survey of published trials, we focus on relation between eligibility criteria and effectiveness of intercalated treatment.

Methods. Published documents were identified using major medical databases, conference proceedings and references of published trials. Median progression-free survival (PFS) was taken as the basic parameter of treatment efficacy. Correlation between characteristics of patients and median PFS was assessed through the Pearson’s correlation coefficient and the coefficient of determination, separately for first-line and second-line setting.

Results. The series includes 11 single-arm trials and 18 randomized phase II or phase III trials with a total of 2903 patients. Treatment-naive patients or those in progression after first-line treatment were included in 16 and 13 trials, respectively. In 14 trials, only patients with non-squamous histology were eligible. Proportion of patients with non-squamous carcinoma (in first-line setting), proportion of never-smokers (both in first- and second-line setting) and proportion of epidermal growth factor receptor (EGFR) mutant patients (both in first- and second-line setting) showed a moderate or strong correlation with median PFS. In six trials of intercalated treatment applied to treatment-naive EGFR-mutant patients, objective response was confirmed in 83.1% of cases and median PFS was 18.6 months.

Conclusions. Most suitable candidates for intercalated treatment are treatment-naive patients with EGFR–mutant tumors, as determined from biopsy or liquid biopsy. For these patients, experience with intercalated treatment is most promising and randomized trials with comparison to the best standard treatment are warranted.

Key words: NSCLC; intercalated treatment; EGFR; tyrosine-kinase inhibitors

Introduction

Soon after the discovery of activating mutations of epidermal growth factor receptor (EGFR) and of their crucial role in determining sensitivity to tyrosine kinase inhibitors (TKIs), several trials confirmed the advantage of TKIs in comparison to chemotherapy for patients with advanced non-
small cell lung cancer (NSCLC) with activating EGFR mutations.\textsuperscript{1-5} Due to higher response rate, longer time to progression and less toxicity, monotherapy with TKIs has been approved as the preferred first-line treatment for these patients. TKIs clearly improve short-term prognosis of patients with EGFR mutant lung cancer. Still, after a median interval of around one year, patients on treatment with TKIs develop resistance and experience disease progression.\textsuperscript{6} New treatments, either as first-line or at progression are needed.\textsuperscript{7}

After huge disappointment due to four large negative trials of chemotherapy alone versus chemotherapy combined with continuous application of gefitinib or erlotinib\textsuperscript{8-11}, the idea of combining TKIs with chemotherapy never fully recovered. Many research groups simply concluded that the two categories of drugs should not be used together and most of current pre-clinical and clinical research focuses on new drugs designed to overcome primary or acquired resistance to TKIs.\textsuperscript{12-14} The fact that the four trials were unselected regarding histology and smoking status received little attention. For a quarter of patients in the TRIBUTE trial, the status of EGFR mutations was later determined: when treated with the combination in comparison to chemotherapy alone, EGFR mutant patients had higher response rate and a trend towards longer progression-free survival (PFS), but no advantage in overall survival (OS).\textsuperscript{15}

In spite of prevailing disappointment, some researchers insisted that the negative message of the four large trials should be accepted as new knowledge rather than ignored and developed the concept of intercalated treatment. The reasoning was clear: when applied concomitantly with chemotherapy, TKIs induce G1-phase cell-cycle arrest, due to which cell-cycle dependent chemotherapeutic agents will not be effective.\textsuperscript{16} Chemo-refractoriness of cells harboring sensitizing-EGFR mutations in the presence of gefitinib was confirmed \textit{in vitro}.\textsuperscript{17} Time separation with an interval of 6 days without TKIs to restore chemosensitivity of tumor cells should remove this mutual antagonism, so as to benefit from the efficacy of both classes of drugs.\textsuperscript{18} Additional support for the concept of intercalated treatment came from laboratory experiments and from a clinical trial of sequential application of chemotherapy and TKI: proper sequence starting with cytotoxic drugs, followed by TKIs leads to their synergistic activity.\textsuperscript{19-23}

So far, a few dozen clinical trials on intercalated treatment with chemotherapy and TKIs have been published. A recent review focused on trials with randomization between intercalated schedules and chemotherapy alone.\textsuperscript{24} While such a review is definitively valuable, a reader is confused when facing a list of trials with a wide range of eligibility criteria, leading to diverging conclusions. This review paper has a different goal. We believe that before proceeding with further clinical research, we should understand which patients will most likely benefit from intercalated treatment. Only after defining the optimal target population, future trials can be designed to compare intercalated treatment to the best standard treatment in those selected patients.

\section*{Methods}

\subsection*{Selection of publications for analysis}

Published papers and conference reports on intercalated therapy for NSCLC were eligible for review. Intercalated treatment was defined as a treatment with cytotoxic drug(s), combined with an EGFR-TKI during a part of a treatment cycle. Trials on chemotherapy combined with continuous application of TKIs or a gap of less than 4 days, and trials using alternating cycles of cytotoxic drugs and of TKIs were not included in this review.

Pubmed was used to search for published trials on intercalated treatment for NSCLC, with the following descriptors and limits: NSCLC; chemotherapy and (erlotinib and/or gefitinib and/or afatinib); clinical trial; 2006-2016 as the publication period; humans; English language. This initial search led to 686 publications. The list was then manually reviewed. Additional publications were identified using Web of Science cross-citation database, proceedings of major conferences during the past 4 years (IASLC World Lung Cancer Conference, ASCO, ESMO, European Lung Cancer Conference) and the list of references in published trials.

\subsection*{Analysis of published experience}

Selected papers were analyzed, with focus on selection criteria and parameters of efficacy. Information on the proportion of patients with EGFR mutant tumors was often incomplete or missing. If not available in the text, an estimate on the proportion of patients with EGFR mutant disease was made. As the first step, all patients with squamous histology were considered as EGFR wild-type (EGFR wt). In case of non-squamous histology, an estimate was based on proportion of never-smokers vs. smokers.
and on ethnicity, using published meta-analysis on global pattern of EGFR mutations.25

Due to the wide spectrum of eligibility criteria and of comparator arms, randomized trials were not considered an appropriate basis for analysis of efficacy of the intercalated treatment. We therefore chose a different approach. Experience from single-arm phase II trials and from the intercalated arm of randomized trials was analyzed in relation to histology, smoking status and EGFR mutation status, separately for treatment-naive and pre-treated patients. Median PFS was taken as a conventional indicator of efficacy.

Statistical analysis

Statistical analysis was limited to intercalated treatment, either in non-randomised trials or in the intercalated arm of randomised trials. The strength of correlation between proportion of non-squamous tumors, proportion of non-smokers and proportion of EGFR-mutation positive cases with median PFS was evaluated calculating the Pearson’s correlation coefficient (R) and the coefficient of determination (R-squared; R²). Pearson’s R is a simple measure of the linear correlation between two variables, giving a value between +1 and −1, where +1 is a total positive correlation, 0 is the absence of correlation, and −1 is a total negative correlation. The coefficient of determination is such that 0 ≤ R² ≤ 1: although there are no specific cut-offs to define a moderate, or a strong correlation, a higher R² score indicates a stronger association.

Correlations were graphically described by bubble plots, where each bubble represents a study, with bubble size proportional to the number of patients included in each study. As all the analyses were weighted by sample size of each study, weighted least-squares regression line was calculated and reported in each graph.

Statistical analyses were conducted using SPlus (S-PLUS 6.0 Professional, release 1; Insightful Corporation, Seattle, WA, USA). Graphs were realized using SigmaPlot (Systat Software, San Jose, CA).

Results

Identification of publications for analysis

After the initial search through PubMed, 96 reports were selected to which 4 trials found through conference proceedings and 6 trials identified by cross-citation database were added for a total of 106 studies. A total of 29 trials were considered eligible for the analysis (Figure 1). The series includes 11 single-arm phase II trials, 16 randomized phase II trials and 2 phase III randomized trials, with a total of 2903 patients.26-54

Eligibility criteria and treatments used

Fourteen trials were limited to non-squamous histology, while 15 included patients with any histologic type of NSCLC. Sixteen trials were open only for treatment-naive patients, while 13 included those in progression after first-line treatment. The proportion of never-smokers was specified in all but two reports.

Five trials were limited to EGFR mutant disease and 4 to patients with EGFR wild-type or unknown tumors. Another 3 trials included a substantial proportion of EGFR mutant cases and separately reported the experience for this subpopulation of patients. Nine of the remaining 17 trials included information on EGFR status for some of their patients, but the proportion analyzed was usually low and thus inappropriate for any analysis.
### TABLE 1. Randomized trials on intercalated chemotherapy and TKIs for non-small cell lung cancer

| REFERENCE          | TYPE OF TRIAL | # OF PTS | SELECTION OF PATIENTS                                      | TREATMENT REGIMEN(s)                                                                 | % never-smokers | % EGFR mutant, intercalated arm only | ORR (%) | MEDIAN PFS (months) | MEDIAN OS (months) |
|--------------------|---------------|----------|-------------------------------------------------------------|---------------------------------------------------------------------------------------|-----------------|-------------------------------------|----------|---------------------|---------------------|
| Mok 2009 (FASTACT) | Randomized    | 154      | All histologies, previously untreated                       | Arm A (76 pts): Gem, d 1 & 8 Cis or Carbo, d 1 Erlotinib, d 15-28 Cycle q 4 weeks Arm B (78 pts): as above, placebo instead of Erlotinib | 34%             | Arm A: 35.5% Arm B: 24.4%           | P = 0.12 | Arm A: 6.9 m Arm B: 5.5 m | Arm A: 17.3 m Arm B: 17.7 m |
|                   | Phase 2       |          |                                                             |                                                                                       |                 |                                     |          |                     |                     |
| Hirsch 2011       | Randomized    | 143      | Positive for EGFR protein expression and/or with high EGFR gene copy number, previously untreated | Arm A (71 pts): Praci d 1 Carbo d 1 Erlotinib d 2 - 15 Cycle q 3 weeks Arm B (72 pts): Erlotinib | 28%             | Arm A: 22.4% Arm B: 11.6%           | P = ns   | Arm A: 4.6 m Arm B: 2.7 m | Arm A: 11.4 m Arm B: 16.7 m |
|                   | Phase 2       |          |                                                             |                                                                                       |                 |                                     |          |                     |                     |
| Aerts 2012        | Randomized    | 231      | All histologies, progression after platinum-based chemotherapy | Arm A (115 pts): Erlotinib Arm B (116 pts): Doce or Pem, d 1 Erlotinib, d 2 – 16 Cycle q 3 weeks | 7%              | Arm A: 7% Arm B: 13%               | P = 0.03 | Arm A: 4.9 m Arm B: 6.1 m | Arm A: 5.5 m Arm B: 7.8 m |
|                   | (NVALT 10)    |          |                                                             |                                                                                       |                 |                                     |          |                     |                     |
| Lee 2013          | Randomized    | 240      | Non-squamous, never-smokers, progression after 1st line chemotherapy | Arm A (78 pts): Pem d 1 Erlotinib Arm B (82 pts): Erlotinib continuously Arm C (80 pts): Pem d 1 Cycle q 3 weeks | 100%            | Arm A: 44.7% Arm B: 29.3% Arm C: 10.0% | P = 0.001| Arm A: 7.4 m Arm B: 3.8 m Arm C: 4.4 m | Arm A: 20.5 m Arm B: 22.8 m Arm C: 17.7 m |
|                   | Phase 2       |          |                                                             |                                                                                       |                 |                                     |          |                     |                     |
| Wu Y-L 2013       | Randomized    | 451      | All histologies, previously untreated                       | Arm A (226 pts): Gem, d 1 & 8 Cis or Carbo, d 1 Erlotinib, d 15-28 Cycle q 4 weeks Arm B (225 pts): as above, placebo instead of Erlotinib | 49%             | Arm A: 44% Arm B: 16%               | P = 0.0001| Arm A: 7.6 m Arm B: 6.0 m | Arm A: 18.3 m Arm B: 15.2 m |
|                   | (FASTACT 2)   |          |                                                             |                                                                                       |                 |                                     |          |                     |                     |
| Auliac 2014       | Randomized    | 147      | EGFR wild-type or unknown, progression after 1st line chemotherapy | Arm A (73 pts): Doce, d 1 Erlotinib, d 2 – 16 Cycle q 3 weeks Arm B (74 pts): Doce, d 1 | 7.5%            | Arm A: 4.4% Arm B: 1.4%            | P = ns   | Arm A: 2.2 m Arm B: 2.5 m | Arm A: 6.5 m Arm B: 8.3 m |
|                   | Phase 2       |          |                                                             |                                                                                       |                 |                                     |          |                     |                     |
| Karavasilis 2014  | Randomized    | 50       | All histologies, previously untreated                       | Arm A (25 pts): Doce, d 1 Erlotinib, d 9 – 20 Arm B (25 pts): Doce, d 1 Erlotinib, d 3 – 14 Cycle q 3 weeks | 10%             | Arm A: 24% Arm B: 12%              | P = 0.001| Arm A: 2.9 m Arm B: 4.2 m | Arm A: 9.9 m Arm B: 10.8 m |
|                   | Phase 2       |          |                                                             |                                                                                       |                 |                                     |          |                     |                     |
| Mok 2014          | Randomized    | 123      | Unselected, progression after platinum-based ChT            | Arm A (63 pts): Eribulin mesylate, d 1 Erlotinib, d 2-16 Cycle q 3 weeks Arm B (60 pts): Eribulin mesylate, d 1 and d 8 Erlotinib, d 15-28 Cycle q 4 weeks | 24%             | Arm A: 13% Arm B: 17%             | P = ns | Arm A: 3.5 m Arm B: 3.8 m | Arm A: 7.6 m Arm B: 8.5 m |
|                   | Phase 2       |          |                                                             |                                                                                       |                 |                                     |          |                     |                     |
| REFERENCE       | TYPE OF TRIAL | # OF PTS | SELECTION OF PATIENTS                                                                 | TREATMENT REGIMEN(s)                                                                 | % never-smokers | % EGFR mutant, intercalated arm only | ORR (%) | MEDIAN PFS (months) | MEDIAN OS (months) |
|-----------------|---------------|----------|--------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|-----------------|------------------------------------|----------|---------------------|---------------------|
| Yu 2014 12      | Randomized    | 117      | Non-squamous, previously untreated                                                   | Arm A (58 pts): Pem, d 1; Cis or Carbo, d 1; Gefitinib, d 3 – 16 Cycle q 3 weeks Arm B (57 pts): As above, no Gefitinib | 58%             | 40%                                | 50.0%    | 7.9 m               | 20.8 m             |
|                 | Phase 2       |          |                                                                                        | Arm A: 7 m; Arm B: 7.0 m                                                          | P = ns          |                                    | Arm A: 25.4 m       |                     |
|                 |               | 32       | As above, subgroup with activating EGFR mutations                                     | Arm A: 14 pts; Arm B: 18 pts Treatment as above                                    | Not separately reported | Arm A: 76.9% | Arm B: 50.0% | Arm A: Not reached | Arm B: 14.0 m       |
|                 |               |          |                                                                                        |                                                                                     | Arm A: 47.7% | Arm B: 47.7% | P = ns | P = ns |                     |
|                 |               |          |                                                                                        | Arm A: 7.9 m; Arm B: 7.0 m                                                          | P = ns          |                                    | Arm A: 20.8 m       |                     |
| Choi 2015 35    | Randomized    | 90       | NSCLC, EGFR wild, type or unknown, PS 0 – 2, previously untreated                     | Arm A (44 pts): Pem, d 1 Carbo, d 1 Gefitinib, d 2 – 15 Cycle q 3 weeks x 4 Maintenance Gefitinib Arm B (46 pts): As Arm A, no Gefitinib | 10%             | 10%                                | 41.9%    | 4.1 m               | 14.0 m             |
|                 | Phase 2       |          |                                                                                        |                                                                                     | Arm B: 39.5% | Arm B: 39.5% | P = ns | P = ns |                     |
|                 |               |          |                                                                                        | Arm A: 4.1 m; Arm B: 4.1 m                                                          | P = ns          |                                    | Arm A: 9.3 m        |                     |
|                 |               |          |                                                                                        | Arm B: 10.5 m                                                                          | P = ns          |                                    |                     |                     |
| Juan 2015 36    | Randomized    | 68       | All histologies Progression after plat-in-based chemotherapy                         | Arm A (33 pts): Docet q 3 weeks Erlotinib, d 2 – 16 Arm B (35 pts): Erlotinib continuously | 6%              | 5%                                 | 3%                   | 4.1 m               | 14.0 m             |
|                 | Phase 2       |          |                                                                                        |                                                                                     | Arm A: 9%      | Arm B: 9% | P = 0.19 | P = 0.09 |                     |
|                 |               |          |                                                                                        | Arm A: 3.0 m; Arm B: 2.1 m                                                          | P = ns          |                                    | Arm A: 7.5 m        |                     |
|                 |               |          |                                                                                        | Arm B: 5.2 m                                                                          | P = 0.09       |                                    |                     |                     |
| Lu 2015 37      | Randomized    | 219      | Adenocarcinoma, EGFR unknown, previously untreated                                    | Arm A (109 pts): Gem, d 1 and 8 Carbo, d 1 Gefitinib d 15-25 and maintenance Cycle q 4 weeks x 4 Arm B (110 pts): As above, no Gefitinib | 100%            | 72%                                | 76.9%    | Not reached | Not reported         |
|                 | Phase 3       |          |                                                                                        |                                                                                     | Arm A: 79.5% | Arm B: 39.5% | P = 0.04 | P = 0.001 |                     |
|                 |               |          |                                                                                        | Arm A: 10 m; Arm B: 4.4 m                                                          | P = 0.19       |                                    | Arm A: 7.5 m        |                     |
|                 |               |          |                                                                                        | Arm B: 5.2 m                                                                          | P = 0.19       |                                    |                     |                     |
| Michael 2015 36 | Randomized    | 54       | All histologies PS 2 or elderly Previously untreated                                  | Arm A (28 pts): Gem d 1 and 8 Erlotinib days 15 – 28 Cycle q 4 weeks Arm B (26 pts): Gem d1 and 8 Cycle q 4 weeks | 15%             | 12%                                | 6%                   | 2.5 m               | 4.4 m             |
|                 | Phase 2       |          |                                                                                        |                                                                                     | Arm A: 23% | Arm B: 23% | P: ns | P: ns | P: ns |
|                 |               |          |                                                                                        | Arm A: 2.5 m; Arm B: 1.9 m                                                          | P: ns          |                                    | Arm A: 3.9 m        |                     |
|                 |               |          |                                                                                        | Arm B: 4.4 m                                                                          | P: ns          |                                    |                     |                     |
| Han 2016 37     | Randomized    | 121      | Adenocarcinoma, EGFR mutant, previously untreated                                    | Arm A (40 pts): Gem, d1 + maintenance Carbo, d1 for ≤ 6 cycles Gefitinib, d 5-21 + maintenance Cycle q 4 weeks x 4 Arm B (40 pts): As above, no Gefitinib Arm C (41 pts): Gefitinib alone | Not reported | 100%                               | 82.5%    | Not reached | Not reached         |
|                 | Phase 2       |          |                                                                                        |                                                                                     | Arm A: 65.9% | Arm B: 65.9% | P: not reported | P: not reported |                     |
|                 |               |          |                                                                                        | Arm A: 18.8 m; Arm B: 12.0 m                                                         | P: 0.04        |                                    | Arm A: 18.8 m       |                     |
|                 |               |          |                                                                                        | Arm C: 65.9%                                                                          | P: not reported |                                    | Arm B: 12.0 m       |                     |
| Lara 2016       | Randomized    | 59       | PS 2, Proteomics: VeriStrat-good status, previously untreated                        | Arm A (33 pts): Erlotinib Arm B (26 pts): Pacl d 1 Carbo d 1 Erlotinib d 2 – 16 Cycle q 3 weeks x 4 Maintenance Erlotinib | 20%             | 20%                                | 6%                   | 1.6 m               | 11.0 m             |
|                 | (SWOG 50709)  |          |                                                                                        |                                                                                     | Arm A: 23% | Arm B: 23% | P = 0.06 | P = 0.06 | P = 0.27 |
|                 | Phase 2       |          |                                                                                        | Arm A: 4.6 m; Arm B: 4.6 m                                                          | P = 0.06       |                                    | Arm A: 6.0 m        |                     |
|                 |               |          |                                                                                        | Arm B: 11.0 m                                                                          | P = 0.27       |                                    |                     |                     |
| Li 2016 41      | Randomized    | 79       | Predominantly nonsquamous Progression after 1st line chemotherapy                    | Arm A (27 pts): Cis q 3 weeks Arm B (52 pts): Cis q 3 weeks Arm C (27 pts): Cis q 3 weeks | Not reported | 19%                                | 5%                   | 1.7 m               | 2.6 m             |
|                 | Phase 2       |          |                                                                                        |                                                                                     | Arm A: 29% | Arm B: 29% | P = 0.17 | P = 0.26 | P = 0.28 |
|                 |               |          |                                                                                        | Arm A: 2.9 m; Arm B: 4.7 m                                                          | P = 0.26       |                                    | Arm A: 8.3 m        |                     |
|                 |               |          |                                                                                        | Arm B: 9.7 m                                                                          | P = 0.28       |                                    |                     |                     |
| Lee 2016 42     | Randomized    | 76       | Adenocarcinoma, never-smokers, Previously untreated                                    | Arm A (39 pts): Cis q 3 weeks Arm B (37 pts): As above, no Gefitinib Arm C (37 pts): Gefitinib for arm B | 100%            | 42%                                | 79.5%    | 12.8 m              | 22.2 m             |
|                 | Phase 2       |          |                                                                                        |                                                                                     | Arm A: 51.4% | Arm A: 51.4% | P = 0.01 | P = 0.009 | P = 0.15 |
|                 |               |          |                                                                                        | Arm A: 12.8 m; Arm B: 7.0 m                                                          | P = 0.009      |                                    | Arm A: 29.2 m       |                     |
|                 |               |          |                                                                                        | Arm B: 20.4 m                                                                          | P = 0.15       |                                    |                     |                     |
Erlotinib and gefitinib were used in 17 and 9 trials, respectively. In 2 trials, either erlotinib or gefitinib was used, while afatinib was used in 1 trial.

Among 18 randomized trials (Table 1), chemotherapy alone was the comparator arm in 10 trials. Four trials used TKI alone as the comparator, 2 trials compared two different intercalated schedules, while 2 trials used 3-arm design with comparison among intercalated schedule, chemotherapy alone or TKIs alone. According to PFS as the most common parameter of efficacy, the intercalated schedule was superior to the comparator in 12 trials, crossing the conventional margin of P < 0.05 in 7 trials. No significant difference was seen in 4 other trials and in 2 trials comparing two different intercalated schedules of intercalated therapy.

Basic data on single-arm Phase 2 trials are presented in Table 2.

### Efficacy of intercalated treatment

Figure 2 shows correlation between median PFS and proportion of patients with non-squamous histology (Panel A), proportion of never-smokers (Panel B) and proportion of EGFR mutant patients (Panel C).

As for tumor histology, there was a moderate correlation between proportion of non-squamous tumors and median PFS in the first-line setting ($R = 0.61$, $R^2 = 0.38$, $p = 0.02$). The slope of the regression line (0.23) suggests that a 10% increase in the proportion of non-squamous tumors corresponds to a 2.3-months improvement in median PFS in first-line. On the other hand, the correlation was very weak in the second-line setting ($R = 0.09$, $R^2 = 0.01$, $p = 0.77$).

As for smoking status, there was a moderate correlation between proportion of non-smokers and median PFS, both in the first-line and in the second-line setting (first-line: $R = 0.55$, $R^2 = 0.30$, $p = 0.04$; second-line: $R = 0.65$, $R^2 = 0.42$, $p = 0.02$). In detail, the slope of the regression line (0.09 for the first-line and 0.05 for the second-line) suggests that a 10% increase in the proportion of non-smokers corresponds to a 0.9-months improvement in median PFS in first-line, and to a 0.5-months improvement in median PFS in second-line.

![Figure 2](image-url)

**FIGURE 2.** Correlation between median PFS and proportion of patients with non-squamous histology (A), proportion of never-smokers (B) and proportion of EGFR mutant patients (C). Black solid marks and black solid lines are for 1st line treatment; red hollow marks and red interrupted lines for 2nd line treatment. Bubble size corresponds to the number of patients in a trial.
As for EGFR mutational status, there was a strong correlation between proportion of EGFR mutation-positive tumors and median PFS, both in the first-line and in the second-line setting (first-line: $R = 0.91$, $R^2 = 0.83$, $p < 0.0001$; second-line: $R = 0.69$, $R^2 = 0.48$, $p = 0.006$). The slope of the regression line (0.16 for the first-line and 0.06 for the second-line) suggests that a 10% increase in the proportion of EGFR mutation-positive tumors corresponds to a 1.6-months improvement in median PFS in first-line, and to a 0.6-months improvement in median PFS in second-line.

Six trials on treatment-naive patients with EGFR mutant disease reported excellent response rate of 83.1% (range: 76.9% to 84.2%).30,34,39,42,52,54 Five of these trials presented data on median PFS ranging from 13.3 to 23.4 months (median PFS for all 5 trials: 18.6 months). This figure does not include an

**TABLE 2.** Single-arm Phase II trials on intercalated chemotherapy and TKIs for non-small cell lung cancer

| REFERENCE      | # OF PTS | SELECTION OF PATIENTS | TREATMENT REGIMEN(s) | % never-smokers | % EGFR mutant | ORR (%) | MEDIAN PFS (months) | MEDIAN OS (months) |
|----------------|----------|-----------------------|----------------------|-----------------|---------------|---------|---------------------|-------------------|
| Oshita 2010    | 16       | Unselected, previously untreated | Pacl d 1, Irino d 1, Gefitinib d 8-14, Cycle q 3 weeks | Not reported | 25%           | 43.8%   | Not reported         | 18.1 m            |
| Sangha 2011    | 39       | All histologies Progression after 1st line chemotherapy | Docetaxel d 1, Etilinib days 2 – 16, Cycle q 3 weeks | 28% | 19%           | 28.2%   | 4.1 m               | 18.2 m            |
| Minami 2013    | 27       | Non-squamous Progression after 1st line chemotherapy | Pemetrexed d 1, Etilinib d 2 – 16, Cycle q 3 weeks | 22% | 4%            | 11.1%   | 2.8 m               | 15.8 m            |
| Yoshimura 2013 | 27       | Activating EGFR mutations, Progression after TKI | Pemetrexed d 1, Etilinib or Gefitinib, days 2 – 16, Cycle q 3 weeks | 78% | 100%          | 25.9%   | 7.0 m               | 11.4 m            |
| Kim 2014       | 17       | Non-squamous, EGFR wt, Progression after 1st line ChT | Pemetrexed d 1, Etilinib d 2-15 | 27% | 0%            | 27.0%   | 2.5 m               | 6.7 m             |
| Fang 2014      | 57       | Unselected, progression after platinum-based ChT | Gemcitabine d 1 and 8, Cis d 1-3, Gefitinib, d 10 - 24, Cycle q 4 weeks | 37% | 40%           | 11%     | 10 m                | 15.2 m            |
| Yang 2014      | 29       | Adenocarcinoma, non-smokers, EGFR unknown, previously untreated | Paclitaxel d 1, Carboplatin d 1, Gefitinib, d 8 – 17 + maintenance, Cycle q 3 weeks | 100% | 73%           | 74.1%   | Not reached |                   |
| Zwitter 2014   | 15       | Adenocarcinoma, light/never smokers, EGFR wild-type or unknown Previously untreated | Gemcitabine d 1 and 4, Cis d 2, Etilinib d 5 – 15, Cycle q 3 weeks x 4 – 6, Maintenance Etilinib | 100% | 5%            | 33%     | 6.0 m               | 7.6 m             |
| Yoshimura 2015 | 26       | Activating EGFR mutations Previously untreated | Pemetrexed d 1, Gefitinib d 2 – 16 | 46% | 100%          | 84.6%   | 18.0 m              | 32.0 m            |
| Yu 2015        | 42       | Mostly adenocarcinoma Progression after response to TKI | Pemetrexed d 1 or Pemetrexed d 1, Erlotinib or Gefitinib, d 6 – 21, Cycle q 3 weeks | 71% | 61%           | 23.8%   | 8.0 m               | 11.0 m            |
| Zwitter 2016   | 38       | Activating EGFR mutations Previously untreated | Gemcitabine d 1 and 4, Cis d 2, Etilinib d 5 – 15, Cycle q 3 weeks x 4 – 6, Maintenance Etilinib | 63% | 100%          | 84.2%   | 23.4 m              | 38.3 m            |

Carbo = carboplatin; Cis = cisplatin; Docetaxel

As for EGFR mutational status, there was a strong correlation between proportion of EGFR mutation-positive tumors and median PFS, both in the first-line and in the second-line setting (first-line: $R = 0.91$, $R^2 = 0.83$, $p < 0.0001$; second-line: $R = 0.69$, $R^2 = 0.48$, $p = 0.006$). The slope of the regression line (0.16 for the first-line and 0.06 for the second-line) suggests that a 10% increase in the proportion of EGFR mutation-positive tumors corresponds to a 1.6-months improvement in median PFS in first-line, and to a 0.6-months improvement in median PFS in second-line.

Six trials on treatment-naive patients with EGFR mutant disease reported excellent response rate of 83.1% (range: 76.9% to 84.2%).30,34,39,42,52,54 Five of these trials presented data on median PFS ranging from 13.3 to 23.4 months (median PFS for all 5 trials: 18.6 months). This figure does not include an
additional trial from this category which reported 86% PFS at 15 months, with no data on median PFS due to relatively short follow-up.

Discussion

Most surveys and meta-analyses focus on the question of efficacy and/or toxicity of a particular new treatment in comparison with the standard approach. This was also the case with intercalated treatment for advanced NSCLC. On the basis of published randomized trials, a recent meta-analysis concluded that intercalated treatment is superior to the comparator arm. While this meta-analysis offered a valuable insight into an area which is not in the main stream of current clinical research, the question of efficacy of intercalated treatment is too complex to be answered by a simple comparison.

A critical look at all published trials reveals great heterogeneity in eligibility criteria including treatment-naïve patients or those in progression after first-line therapy. In addition, we see a whole spectrum of biologically divergent disease: all histologic types or only non-squamous histology; exclusively EGFR–mutant disease, only EGFR–wt tumors or, in most trials, both groups. On such a heterogeneous basis and without considering the optimal standard therapy for a particular population of patients, the value of a new approach cannot be assessed. Is the intercalated treatment superior to chemotherapy alone for EGFR–wt patients or superior to TKI alone for EGFR–mutant patients? To be more concrete: it comes as no surprise that intercalated treatment was superior to chemotherapy alone for a population which included a substantial proportion of EGFR–mutant patients and superior to TKIs alone for a population of predominantly EGFR–wt patients. It is not the intercalated approach, but inclusion of an effective drug into the schedule which may be responsible for the positive experience in these trials. We believe that on the basis of randomized clinical trials published so far, the question of superiority of intercalated schedules over the standard treatment cannot be answered.

Our estimate on the proportion of EGFR mutant patients, as used in the analysis, includes a considerable degree of uncertainty. Only half of trials (14/29) included information on the proportion of EGFR–mutant vs. EGFR–wt tumors for more than 50% of patients. Other trials reported results of EGFR analysis for a minority of patients, or (in 8 publications) no such information. We therefore made an estimate, based on histologic types of tumors (available for 28/29 trials), on proportion of never-smokers (available for 27/29 trials) and on the country where a trial was performed, using tables from a recent meta-analysis. This approach led us to the best possible estimate, but the results should nevertheless be regarded as exploratory and tentative. In future, precise molecular diagnostics should minimize these uncertainties.

Our survey does not include analysis of toxicity of different schedules of intercalated treatment. This aspect was clearly presented in a recent review: apart from the expected skin toxicity and diarrhea, intercalated schedules do not present a disproportional burden to patients.

Relation between selection criteria and effectiveness of intercalated treatment is shown in Figure 2. On the basis of pooled data on median PFS from randomized and single-arm trials, it is clear that pre-treated patients are not good candidates for a treatment which includes a modality to which resistance has already developed. While the proportion of patients with non-squamous histology and of never-smokers determine efficacy of intercalated treatment, EGFR mutations are clearly the strongest predictive factor for longer PFS. By far the greatest benefit was for treatment-naïve patients with activating EGFR mutations. According to trials in which this group of patients was reported separately, their median PFS after intercalated treatment ranged between 13.3 and 23.4 months; median PFS for the pooled data was 18.4 months. This figure is substantially above PFS of 9 to 13 months, as reported for TKIs as monotherapy for EGFR–mutant NSCLC. Response rate was also very high: 83.1%, with a substantial proportion of complete remissions. Our survey is in accordance with a recent editorial and with a meta-analysis, which pointed to intercalated regimens as the most promising first-line treatment for EGFR–mutated NSCLC.

With the introduction of liquid biopsy from peripheral blood, the category of patients with undetermined EGFR mutant status should be very small. In case this new technique is not available, previously untreated never-smokers with non-squamous histology for whom EGFR status cannot be determined should also be considered for trials testing the role of intercalated treatment. Depending on ethnicity, approximately half of them have EGFR mutant tumors, in which case addition of TKI to cytotoxic drugs would be clearly beneficial; the other half with EGFR negative tu-
mors should benefit from cytotoxic drugs included in the intercalated schedule. In future trials of intercalated treatment, pemetrexed with platin appears as the preferred option for the cytotoxic component. Regarding the choice of TKI, virtually all current experience is limited to erlotinib and gefitinib. Still, in view of recent very favorable experience for patients who developed resistance mutations, osimertinib intercalated with chemotherapy deserves to be considered either in first-line setting or for patients in progression after first-generation TKIs.62

In two recent phase II randomized trials, patients with treatment-naive advanced EGFR–mutant NSCLC were treated with continuous gefitinib in combination with chemotherapy. As the comparator arm, sequential gefitinib and chemotherapy or gefitinib alone were applied.63, 64 In both trials, patients on the combination with continuous gefitinib and chemotherapy experienced longer PFS. These reports support the advantage of combined treatment with chemotherapy and TKIs and re-open the dilemma between their concomitant and intercalated application. Combination of TKIs with bevacizumab is another possibility which deserves further attention.65

We are perfectly aware that the correlation we have reported between the proportion of patients with EGFR mutation positive tumor and the median PFS obtained with the intercalated treatment could be reasonably observed also with EGFR inhibitors alone. The only way to assess the real added value of intercalated treatment is a randomized trial with comparison to TKI alone and overall survival as the principal endpoint.

In conclusion, intercalated treatment with cytotoxic drugs and TKIs is a promising approach for patients with previously untreated advanced NSCLC with activating EGFR mutations, as well as for never-smokers with adenocarcinoma and undetermined EGFR status. For these patients, randomized trials with comparison to the optimal standard treatment, or possibly to a third arm with continuous application of TKIs in combination with chemotherapy should define the preferred treatment approach.

**Funding**

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Acknowledgements**

Marjeta Jerala and David Ožura from the Library of the Institute of Oncology Ljubljana provided valuable help in retrieving full-length papers for analysis. Sincere thanks to Lars and Dyanne Søraas for intellectual support and language editing.

**References**

1. Lynch T, Bell D, Sordella R, Gurubhagavatula S, Oki M, Brannigan B, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med* 2004; 350: 2129-39. doi:10.1056/NEJMoa040038

2. Mok T, Wu Y, Thongprasert S, Yang CH, Chu DT, Sajio N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med* 2009; 361: 947-57. doi:10.1056/NEJMoa0810699

3. Zhou C, Wu Y, Chen G, Feng J, Liu X, Wang C, et al. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). *Ann Oncol* 2015; 26: 1877-83. doi:10.1093/annonc/mdv276

4. Sequist U, Yang IC, Yamamoto N, O’Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus gemcitabine in patients with metastatic lung adenocarcinoma with EGFR mutations. *J Clin Oncol* 2013; 31: 3327-34. doi:10.1200/JCO.2012.44.2806

5. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol* 2012; 13: 239-46. doi:10.1016/S1470-2045(11)70393-X

6. Inoue A, Yoshida K, Morita S, Imamura F, Seto T, Okamoto I, et al. Characteristics and overall survival of EGFR mutation-positive non-small-cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients. *Jpn J Clin Oncol* 2016; 46: 462-7. doi.org/10.1093/jjco/hwy014

7. Zhou C, Yao LD. Strategies to improve outcomes of patients with EGFR–mutant non-small-cell lung cancer: Review of the literature. *J Thorac Oncol* 2016; 11: 174-86. doi:10.1092/j.jtho.2015.10.002

8. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 1. *J Clin Oncol* 2004; 22: 777-84. doi:10.1200/JCO.2004.08.001

9. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 2. *J Clin Oncol* 2004; 22: 785-94. doi:10.1200/JCO.2004.07.215

10. Herbst RS, Prager D, Herman R, Klopp B, Johnson BE, Sandler A, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. *J Clin Oncol* 2005; 23: 5892-9. doi:10.1200/JCO.2005.02.840

11. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, et al. Gefitinib versus chemotherapy as first-line treatment of EGFR tyrosine kinase inhibitors: a comparative analysis for 1660 Japanese patients. *Jpn J Clin Oncol* 2012; 42: 140-9. doi:10.1093/jjco/hyr115

12. Ratti M, Tomassello G. Emerging combination therapies to overcome resistance in EGFR-driven tumors. *Anticancer Drugs* 2014; 25: 127-39. doi:10.1097/01.CAD.000000000000035

13. Steuer CE, Khuri FR, Ramalingam SS. The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer. *Cancer* 2015; 121: E1-E6. doi:10.1002/cncr.29139

14. Jänne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer: *N Engl J Med* 2015; 372: 1689-99. doi:10.1056/NEJMoa1411817
15. Eberhard DA, Johnson BE, Amrler LC, Goddard AD, Heldens SL, Herbst RS, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. *J Clin Oncol* 2005; 23: 5900-908. doi:10.1200/JCO.2005.02.857.

16. Reck M. Beyond the TRIBUTE trial: integrating HER1/EGFR tyrosine kinase inhibitors with chemotherapy in advanced NSCLC. *Future Oncol* 2006; 2: 47-51. doi:10.2217/14796694.2.1.47.

17. Tsai CM, Chen JT, Chiu CH, Lai CL, Hsiao SY, Chang KT. Combined epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and chemotherapy in non-small-cell lung cancer: chemo-refractoriness of cells harboring sensitizing-EGFR mutations in the presence of gefitinib. *Lung Cancer* 2013; 82: 305-12. doi:10.1016/j.lungcan.2013.08.028.

18. Davies AM, Ho C, Lara PN Jr, Mack P, Gumerlock PH, Gandara DR. Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. *Clin Lung Cancer* 2006; 7: 385-8. doi:10.1016/j.clincan.2006.n0.021.

19. Mahaffey CM, Davies AM, Lara PN Jr, Pryde B, Holland W, Mack PC, et al. Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation. *Clin Lung Cancer* 2007; 8: 548-53. doi:10.1016/j.clincan.2007.n0.041.

20. Piperdi B, Ling Y-H, Kroog G, Perez-Soler R. Schedule-dependent interaction between epidermal growth factor receptor inhibitors (EGFRi) and G2/M blocking chemotherapeutic agents (G2/M) on human NSCLC cell lines in vitro. *J Clin Oncol* 2004; 22(14S): 7028. PMID: 15260690.

21. Solit DB, She Y, Lobis KC, Scher HI, Rosen N, et al. Pulsatile administration of epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. *Clin Cancer Res* 2005; 11: 1968-9. doi:10.1158/1078-0432.CCR-04-1347.

22. Bartholomew C, Yamashita S, Oka T, Koto M, Ueno NT. Gemcitabine inhibits gefitinib resistance in EGFR-overexpressing cancer cells through downregulation of Akt. *J Cancer* 2011; 2: 435-42. doi:10.7150/jca.2.2435.

23. Kanda S, Horinouchi H, Fujiwara Y, Nokihara H, Yamamoto N, Sekine I, et al. Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy. *Lung Cancer* 2012; 81: 287-93. doi:10.1016/j.lungcan.2015.06.016.

24. La Salvia A, Rossi A, Galetta D, Gobbiini E, De Luca E, Novello S, et al. Intercalated chemotherapy and epidermal growth factor receptor inhibitors for patients with advanced non-small-cell lung cancer: A systematic review and meta-analysis. *Clin Lung Cancer* 2017; 18: 23-33. doi:10.1016/j.jclincan.2016.08.006.

25. Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small cell lung cancer with adenocarcinoma histology: a systematic review and global map by ethnicity (mutMap1). *Am J Respir Crit Care Med* 2015; 5: 2892-11. PMID: 26609494.

26. Mok TS, Wu YL, Lee JS, Thongprasert S, Yu CJ, Zhang L, et al. Randomized phase II study of intercalated gefitinib versus pemetrexed alone as second-line treatment of patients with advanced non-squamous non-small lung cancer: A randomized phase II trial. *J Clin Oncol* 2015; 33(18S): abstr 2887S. PMID: 28016090.

27. Auliac JB, Chouaid C, Greillier L, Monnet I, Le Caer H, Falchero L, et al. Phase II study of intercalated gefitinib plus gemcitabine versus gemcitabine monotherapy as first-line therapy in elderly or ECOG PS 2 patients with advanced NSCLC. *Asia-Pac J Clin Oncol* 2015; 11: 4-14. doi:10.1111/ajco.12178.

28. Han B, Zhang Y, Jin B, Chu T, Gu A, Xu J. Combination of chemotherapy and gefitinib as first-line treatment of patients with advanced adenocarcinoma and sensitive EGFR mutations: a randomized controlled trial. *J Thorac Oncol* 2016; 11(suppl 4): S113-4. doi:10.1016/j.jto.2016.09.007.

29. Lu S, Jian H, Liu W, Yong MQ, Huang JF, Feng J, et al. Intercalating and maintenance use of gefitinib plus chemotherapy versus chemotherapy alone in selected advanced NSCLC (ISCAN-COMET-1002): a multicentre, open-label, randomised, phase 3 study. [abstract]. *J Clin Oncol* 2015; 33(suppl 33): abstr 8042. ClinicalTrials.gov Identifier: NCT01404260.

30. Michael M, White SC, Abdi E, Nott L, Clingen P, Zimet A, et al. Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine combined with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS 2 patients with advanced NSCLC. *Am J Clin Oncol* 2015; 38(4): 420-5. doi:10.1097/JCO.2015.11.003.

31. Li T, Piperdi B, Walsh WV, Kim M, Beckett A, Gucalp R, et al. Randomized phase II study of pharmacodynamic separation of pemetrexed and intercalated erlotinib versus pemetrexed alone for advanced non-small cell lung cancer: *J Clin Oncol* 2017; 35(18S): abstr 1597. doi:10.1200/JCO.2017.35.18_suppl.

32. Lee JS, Lee YJ, Kim HY, Nam B-H, Lee GK, Kim HT, et al. Randomized phase II trial of intercalated gefitinib (G) and pemetrexed/ipilimumab (P/N/G) for never-smokers with chemo-naive stage IIIIB/IV lung adenocarcinoma (LADC). [abstract]. *J Clin Oncol* 2016; 34: e20505. ClinicalTrials.gov Identifier: NCT01502202.

33. Yoon S, Lee D-H, Kim D, Choi C-M, Kim S-W. Randomized Phase II trial comparing intercalation of afatinib to pemetrexed with pemetrexed alone after failure of platinum doublet therapy. [abstract] *J Thorac Oncol* 2017, 12(Suppl 1): S592. abstr P2.03A-061.

34. Oshita F, Saito H, Murakami S, Kondo T, Yamada K. Phase II study of paclitaxel and irinotecan with intercalated gefitinib in patients with advanced non-small-cell lung cancer. *Am J Clin Oncol* 2010; 33: 66-9. doi:10.1097/CCO.0b013e3181b9c0d6.

35. Sangha R, Davies AM, Lara PN Jr, Mack PC, Beckett LA, Hesketh P, et al. Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase II trial. *J Thorac Oncol* 2011; 6: 2112-9. doi:10.1016/j.jto.2013.01.226.061.
Minami S, Kijima T, Hamaguchi M, Nakatani T, Koba T, Takahashi R, et al. Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status. Lung Cancer 2013; 82: 271-5. doi:10.1016/j.lungcan.2013.07.022

Yoshimura N, Oshikho K, Mitsuoka S, Kimura T, Kawaguchi T, Kobayashi M, et al. Prospective assessment of continuation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of pemetrexed. J Thorac Oncol 2013; 8: 96-101. doi:10.1097/JTO.0b013e3182762b6f

Kim YH, Nishimura T, Ozasa H, Nagai H, Sakamori Y, Iwata T, et al. Phase II study of pemetrexed and erlotinib in pretreated nonsquamous non-small-cell lung cancer patients without an EGFR mutation. Chemotherapy 2013; 59: 414-9. doi:10.1159/000363731

Yang J, Lin RY, Sun MX, Wang Q, Zhao YL, Yu JL, et al. Efficacy and survival-associated factors with gefitinib combined with cisplatin and gemcitabine for advanced non-small cell lung cancer. Asian Pac J Cancer Prev 2014; 15: 10967-70. doi:10.7314/APJCP.2014.15.24.10967

Chen YM, Lai CH, Chang HC, Chao TY, Tseng CC, Fang WF, et al. The impact of clinical parameters on progression-free survival of non-small cell lung cancer patients harboring EGFR-mutations receiving first-line EGFR-tyrosine kinase inhibitors. Lung Cancer 2015; 90: 65-70. doi:10.1016/j.lungcan.2015.06.002

Yu S, Zhang B, Xiang C, Shu Y, Wu H, Huang X, et al. Prospective assessment of pemetrexed or pemetrexed plus platinum in combination with gefitinib or erlotinib in patients with acquired resistance to gefitinib or erlotinib: a phase II exploratory and preliminary study. Clin Lung Cancer 2015; 16: 121-27. doi:10.1016/j.clincr.2014.09.007

Zwitter M, Stanič K, Rajer M, Kern I, Vrankar M, Edelebaher N, et al. Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations. Radiol Oncol 2014; 48: 361-8. doi:10.2478/raon-2014-0038

Yoshimura N, Kudoh S, Mitsuoka S, Yoshimoto N, Oka T, Nakai T, et al. Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with non-small cell lung cancer harbouring a sensitive EGFR mutation. Lung Cancer 2015; 90: 65-70. doi:10.1016/j.lungcan.2015.06.002

Yu S, Zhang B, Xiang C, Shu Y, Wu H, Huang X, et al. Prospective assessment of pemetrexed or pemetrexed plus platinum in combination with gefitinib or erlotinib in patients with acquired resistance to gefitinib or erlotinib: a phase II exploratory and preliminary study. Clin Lung Cancer 2015; 16: 121-27. doi:10.1016/j.clincr.2014.09.007

Zwitter M, Rajer M, Stancik C, Vrankar M, Doma A, Cuderman A, et al. Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations. Cancer Biol Ther 2016; 17: 833-9. doi:10.1080/15384047.2016.1195049

Chen YM, Lai CH, Chang HC, Chao TY, Tseng CC, Fang WF, et al. The impact of clinical parameters on progression-free survival of non-small cell lung cancer patients harboring EGFR-mutations receiving first-line EGFR-tyrosine kinase inhibitors. Lung Cancer 2016; 93: 47-54. doi:10.1016/j.lungcan.2016.01.001

De Grève J, Van Meerbeek J, Vansteenkiste JF, Decoster L, Meert AP, Vuylsteke P, et al. Prospective evaluation of first-line erlotinib in advanced non-small cell lung cancer (NSCLC) carrying an activating EGFR mutation: A multicenter academic phase II study in Caucasian patients (FIETI). PLoS One 2016; 11: e0147599. doi:10.1371/journal.pone.0147599

Douillard JY, Ostoros G, Cobo M, Guileau T, McCormack R, Webster A, et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Cancer 2014; 110: 55-62. doi:10.1038/bjc.2013.721

Inoue A, Yoshida K, Morita S, Imamura F, Seto T, Okamoto I, et al. Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients. Jpn J Clin Oncol 2016; 46: 462-7. doi:10.1093/jjco/hyv014

Rossi A. Chemotherapy plus intercalated or continuous EGFR-TKI in advanced non-small cell lung cancer. Trans Cancer Res 2016; 5(Suppl 4): S659-63.

Lopes G, Tan PS, Acharya S, Bilger M, Haaland B. Network meta-analysis comparing first-line therapies and maintenance regimens in EGFR mutated advanced non-small-cell lung cancer (NSCLC). [abstract]. J Clin Oncol 2016; 34(Suppl): abstr e20570.